Home / Doxorubicin / Czechia
CZ ATC L01DB01 · updated 2 Nov 2026
Doxorubicin shortage in Czechia
Is there a Doxorubicin shortage in Czechia?
Yes. As of 2 Nov 2026, 4 Doxorubicin products are reported short in Czechia, the first since 29 Jun 2026. The company estimate for the return is 30 Nov 2026 (latest 25 Mar 2027). Main reason: manufacturing problem.
Also short in Canada, Germany, Italy, Ireland, Austria, Belgium, Sweden. All countries.
Affected products in Czechia
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| CZ | DOXORUBICIN PHARMAGEN 2MG/ML 2MG/ML INF CNC SOL 1X25ML | PHARMAGEN CZ s.r.o., Praha | 29 Jun 2026 | 25 Mar 2027 | Manufacturing problem Výrobní důvody |
| CZ | DOXORUBICIN PHARMAGEN 2MG/ML 2MG/ML INF CNC SOL 1X5ML | PHARMAGEN CZ s.r.o., Praha | 29 Jun 2026 | 25 Mar 2027 | Manufacturing problem Výrobní důvody |
| CZ | ZOLSKETIL PEGYLATED LIPOSOMAL 2MG/ML 2MG/ML INF CNC DIS 1X25ML | Accord Healthcare S.L.U., Barcelona | 14 Aug 2026 | 30 Nov 2026 | Manufacturing problem Výrobní důvody |
| CZ | CAELYX PEGYLATED LIPOSOMAL 2MG/ML 2MG/ML INF CNC SOL 1X25ML | Baxter Holding B.V., Utrecht | 1 Sep 2026 | 29 Jan 2027 | Manufacturing problem Výrobní důvody |
Source
SÚKL (State Institute for Drug Control), market reports. Official list. Products whose latest market report is a supply interruption; one row per SÚKL code.